The methodology and results in the paper may also be very easily applied to other regions with scarce drug availability, stated Dr. David Wilson, who offered as the study’s lead writer as a postdoctoral fellow in Blower’s lab and is now at the University of New South Wales in Australia. Related StoriesStudy evaluates efficiency of antiretroviral treatment in HIV-infected childrenStudy: Safe spaces may play critical part in community-based HIV prevention effortsSafe, effective douche-based rectal microbicide can prevent HIV in gay men If policymakers in KwaZulu-Natal – – as well as other resource-constrained regions – – can rationally plan drug allocation, after that modeling like we have carried out can inform these authorities of likely consequences of different allocation strategies, he said.However, we know that only 10-30 percent of patients will react to standard chemotherapy, so it is not surprising our patients had not responded, or possess responded and the tumor has recurred then. In our study 64 percent of patients experienced a partial response, but because we are just treating patients with the BRAF mutation, we are eliminating about 40 percent of melanoma patients who don’t have this mutation and whom we realize will not respond to this treatment. That’s one reason why we are seeing a much higher response than with conventional treatments. ‘In addition, one of the main unwanted effects we’ve seen is that some sufferers develop early, non-melanoma skin cancers such as for example squamous cell skin malignancy. We have become vigilant about this and although they have become easy to cut out, it’s something we are keeping a close eyes on.